SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Slamon D, Clark GM, Wong S, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-182.
  • 2
    Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25: 118-145.
  • 3
    Curigliano G, Viale G, Bagnardi V, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol. 2009; 27: 5693-5699.
  • 4
    Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009; 27: 5700-5706.
  • 5
    Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol. 2009; 26: 5697-5704.
  • 6
    Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med. 2007; 357: 39-51.
  • 7
    Romond EH, Perez EA, Bryant J, et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer—combined analysis of NSABP-B31/NCCTG-N9831. Paper presented at: Annual Meeting of American Society of Clinical Oncology; Orlando, FL, May 13-17, 2005.
  • 8
    Piccart-Gebhart M. First results of the HERA trial. Paper presented at: Annual Meeting of American Society of Clinical Oncology; Orlando, FL, May 13-17, 2005.
  • 9
    Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-1684.
  • 10
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659-1672.
  • 11
    Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Paper presented at: San Antonio Breast Cancer Symposium; 2005; San Antonio, TX, December 8-11, 2005.
  • 12
    Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354: 809-820.
  • 13
    Edge SB, Byrd DR, Compton CC, et al. American Joint Committee on Cancer (AJCC) cancer staging manual. 7th ed. Chicago, IL: Springer; 2010.
  • 14
    Rodrigues MJ, Wassermann J, Albiges-Sauvin L, et al. Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas. J Clin Oncol. 2010; 28: e541-542.
  • 15
    Untch M, Gelber RD, Jackisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol. 2008; 19: 1090-1096.
  • 16
    American Cancer Society. Cancer facts and figures 2009. Available at: www.cancer.org Accessed January 23, 2011.
  • 17
    Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007; 25: 2127-2132.